GMAB•benzinga•
Genmab Announces Updated Data From Cohort B1 Of The Phase 1/2 RAINFOL-01 Study Of Rinatabart Sesutecan; Showed That With A Median On-Study Follow-Up Of 48 Weeks, Led To A Confirmed Objective Response Rate Of 55.6% And Median Duration Of Response Was Not R
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 17, 2025 by benzinga